These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 22754278)

  • 1. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
    Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
    J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
    Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
    MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
    Torres T; Faria R
    Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating the Science of Psoriasis.
    Gordon KB
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S64. PubMed ID: 27526392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent treatment of chronic psoriasis and asthma with ustekinumab.
    Amarnani A; Rosenthal KS; Mercado JM; Brodell RT
    J Dermatolog Treat; 2014 Feb; 25(1):63-6. PubMed ID: 23469809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
    Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
    Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E; Campanati A; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-clinical comparative study of IL-23 antibodies in psoriasis.
    Zhou L; Wang Y; Wan Q; Wu F; Barbon J; Dunstan R; Gauld S; Konrad M; Leys L; McCarthy R; Namovic M; Nelson C; Overmeyer G; Perron D; Su Z; Wang L; Westmoreland S; Zhang J; Zhu R; Veldman G
    MAbs; 2021; 13(1):1964420. PubMed ID: 34460338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.